Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07919977Phase 2Recruiting
- Sponsor
- Liping Dou
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hematologic diseases comparing Romiplostim Group with Best Supportive Care Group (2 arms). Primary endpoint: Platelet Engraftment Rate at 30 days. Started Jun 2026; status: recruiting.
02
Drugs
romiplostim
03
Conditions
hematologic diseases
Beyond the preview
Go deeper on NCT07919977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919977.